ARTICLE | Company News
Strata to screen patients for Phase I of CBT's CBT-101
December 14, 2018 8:02 PM UTC
CBT Pharmaceuticals Inc. (Pleasanton, Calif.) and Strata Oncology Inc. (Ann Arbor, Mich.) partnered to enroll patients in a Phase I trial evaluating CBT-101 to treat c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)-dysregulated malignancies. Strata will use its genomic screening platform to refer Met-amplified, Met-mutation and Met-fusion advanced patients to the trial...
BCIQ Target Profiles
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)